These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 19101104)

  • 1. (18)F-FDG-PET/CT of orofacial tumors, a value of whole-body imaging approach.
    Ferda J; Ferdová E; Záhlava J; Walter J; Mukensnabl P; Daum O; Kreuzberg B
    Eur J Radiol; 2010 Feb; 73(2):241-8. PubMed ID: 19101104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET/CT for the staging and follow-up of patients with malignancies.
    Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
    Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of whole-body PET/CT, dedicated high-resolution head and neck PET/CT, and contrast-enhanced CT in preoperative staging of clinically M0 squamous cell carcinoma of the head and neck.
    Rodrigues RS; Bozza FA; Christian PE; Hoffman JM; Butterfield RI; Christensen CR; Heilbrun M; Wiggins RH; Hunt JP; Bentz BG; Hitchcock YJ; Morton KA
    J Nucl Med; 2009 Aug; 50(8):1205-13. PubMed ID: 19617339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-FDG PET/CT for staging of penile cancer.
    Scher B; Seitz M; Reiser M; Hungerhuber E; Hahn K; Tiling R; Herzog P; Reiser M; Schneede P; Dresel S
    J Nucl Med; 2005 Sep; 46(9):1460-5. PubMed ID: 16157528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
    Metser U; Even-Sapir E
    Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site.
    Pelosi E; Pennone M; Deandreis D; Douroukas A; Mancini M; Bisi G
    Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):15-22. PubMed ID: 16557200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET monitoring of therapy response in head and neck squamous cell carcinoma.
    Schöder H; Fury M; Lee N; Kraus D
    J Nucl Med; 2009 May; 50 Suppl 1():74S-88S. PubMed ID: 19380408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up?
    Chen W; Jian W; Li HT; Li C; Zhang YK; Xie B; Zhou DQ; Dai YM; Lin Y; Lu M; Huang XQ; Xu CX; Chen L
    Magn Reson Imaging; 2010 Jun; 28(5):613-20. PubMed ID: 20418042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of FDG-PET/CT imaging in head and neck malignant conditions: impact on diagnostic accuracy and patient care.
    Gordin A; Golz A; Keidar Z; Daitzchman M; Bar-Shalom R; Israel O
    Otolaryngol Head Neck Surg; 2007 Jul; 137(1):130-7. PubMed ID: 17599580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer.
    Dirisamer A; Halpern BS; Flöry D; Wolf F; Beheshti M; Mayerhoefer ME; Langsteger W
    Eur J Radiol; 2010 Feb; 73(2):294-9. PubMed ID: 19181468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer.
    Anjos DA; Etchebehere EC; Ramos CD; Santos AO; Albertotti C; Camargo EE
    J Nucl Med; 2007 May; 48(5):764-70. PubMed ID: 17475965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors.
    Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2009 Mar; 45(3):218-24. PubMed ID: 18804404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma.
    Roh JL; Yeo NK; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2007 Oct; 43(9):887-93. PubMed ID: 17207656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraobserver and interobserver variability in GTV delineation on FDG-PET-CT images of head and neck cancers.
    Breen SL; Publicover J; De Silva S; Pond G; Brock K; O'Sullivan B; Cummings B; Dawson L; Keller A; Kim J; Ringash J; Yu E; Hendler A; Waldron J
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):763-70. PubMed ID: 17379435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation.
    Ng SH; Yen TC; Liao CT; Chang JT; Chan SC; Ko SF; Wang HM; Wong HF
    J Nucl Med; 2005 Jul; 46(7):1136-43. PubMed ID: 16000282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI.
    Schöder H; Carlson DL; Kraus DH; Stambuk HE; Gönen M; Erdi YE; Yeung HW; Huvos AG; Shah JP; Larson SM; Wong RJ
    J Nucl Med; 2006 May; 47(5):755-62. PubMed ID: 16644744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
    Wu ZJ; Zhang YX; Wei H; Jia Q
    Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.
    Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ
    J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.
    Fonti R; Salvatore B; Quarantelli M; Sirignano C; Segreto S; Petruzziello F; Catalano L; Liuzzi R; Rotoli B; Del Vecchio S; Pace L; Salvatore M
    J Nucl Med; 2008 Feb; 49(2):195-200. PubMed ID: 18199607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.